Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus.

[1]  Francis Colardyn,et al.  Organizational and ethical aspects of living donor liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  K. Tscheliessnigg,et al.  Sirolimus in patients after liver transplantation. , 2003, Transplantation proceedings.

[3]  G. Loss,et al.  Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  M. Stegall,et al.  Chronic renal dysfunction late after liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  E. Trulock,et al.  Sirolimus-induced leukocytoclastic vasculitis. , 2002, Transplantation.

[6]  R. Calne,et al.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. , 1999, Transplantation.

[7]  G. Alexander,et al.  Sirolimus: a potent new immunosuppressant for liver transplantation. , 1999, Transplantation.

[8]  W. Bechstein,et al.  Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. , 1994, Transplantation.

[9]  H. Bismuth,et al.  Prevalence of dyslipidemia in liver transplant recipients. , 1992, Transplantation.